TG Therapeutics to Host Conference Call on Third Quarter 2022 Financial Results and Business Update
TG Therapeutics (NASDAQ: TGTX) will host a conference call on November 10, 2022, at 8:30 AM ET to discuss its third-quarter 2022 results.
Rhea-AI Summary
TG Therapeutics (NASDAQ: TGTX) will host a conference call on November 10, 2022, at 8:30 AM ET to discuss its third-quarter 2022 results. The call will be led by Michael S. Weiss, Chairman and CEO. Interested parties can participate by calling 1-877-407-8029 (U.S.) or 1-201-689-8029 (international). A live webcast will be available on TG Therapeutics' website, and a recording will be accessible for up to 30 days post-call. The company focuses on developing treatments for B-cell diseases and has completed a Phase 3 program for ublituximab.
Positive
- Upcoming conference call may indicate positive developments in Q3 results.
- Completion of Phase 3 program for ublituximab, targeting B-cell diseases.
Negative
- None.
Details
News Market Reaction – TGTX
The recorded move for TGTX in the trading session of this news was -0.88%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference call to be held Thursday, November 10, 2022 at 8:30 AM ET
NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Thursday, November 10, 2022 at 8:30 AM ET to discuss results for the third quarter of 2022. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS). For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and Linkedin.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.